Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Lauper

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
Clinical Rheumatology|January 23, 2017
The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritisD Alpizar-Rodriguez, Laure Brulhart, Ruediger B Mueller, et al.
RMD Open|November 18, 2021
Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatologyKim Lauper, Joanna Kedra, Maarten de Wit, et al.
Annals of the Rheumatic Diseases|January 21, 2022
EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatologyDelphine Sophie Courvoisier, Kim Lauper, Joanna Kedra, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 6, 2026
Machine Learning to Predict Remission Between Six and 24 Months in Rheumatoid Arthritis: Insights from the JAK-pot CollaborationZubeyir Salis, Denis Mongin, Denis Choquette, et al.
Seminars in Arthritis and Rheumatism|February 21, 2026
Evolution of Janus Kinase inhibitors (JAKi) prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study): effect of regulatory warningsDenis Mongin, Romain Aymon, Denis Choquette, et al.
Joint Bone Spine|December 2, 2023
Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studiesKim Lauper, Denis Mongin, Sytske Anne Bergstra, et al.
Annals of the Rheumatic Diseases|September 13, 2022
After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registriesManuel Pombo-Suarez, Carlos Sanchez-Piedra, Juan Gómez-Reino, et al.
Annals of the Rheumatic Diseases|November 3, 2022
2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseasesGeorge E Fragoulis, Elena Nikiphorou, Mrinalini Dey, et al.
Rheumatology (Oxford, England)|August 19, 2020
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registriesDelphine S Courvoisier, Katarina Chatzidionysiou, Denis Mongin, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 15, 2025
Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs: Data From an International Collaboration of RegistriesRomain Aymon, Denis Mongin, Romain Guemara, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Clinical Rheumatology|January 23, 2017
The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritisD Alpizar-Rodriguez, Laure Brulhart, Ruediger B Mueller, et al.
RMD Open|November 18, 2021
Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatologyKim Lauper, Joanna Kedra, Maarten de Wit, et al.
Annals of the Rheumatic Diseases|January 21, 2022
EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatologyDelphine Sophie Courvoisier, Kim Lauper, Joanna Kedra, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 6, 2026
Machine Learning to Predict Remission Between Six and 24 Months in Rheumatoid Arthritis: Insights from the JAK-pot CollaborationZubeyir Salis, Denis Mongin, Denis Choquette, et al.
Seminars in Arthritis and Rheumatism|February 21, 2026
Evolution of Janus Kinase inhibitors (JAKi) prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study): effect of regulatory warningsDenis Mongin, Romain Aymon, Denis Choquette, et al.
Joint Bone Spine|December 2, 2023
Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studiesKim Lauper, Denis Mongin, Sytske Anne Bergstra, et al.
Annals of the Rheumatic Diseases|September 13, 2022
After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registriesManuel Pombo-Suarez, Carlos Sanchez-Piedra, Juan Gómez-Reino, et al.
Annals of the Rheumatic Diseases|November 3, 2022
2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseasesGeorge E Fragoulis, Elena Nikiphorou, Mrinalini Dey, et al.
Rheumatology (Oxford, England)|August 19, 2020
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registriesDelphine S Courvoisier, Katarina Chatzidionysiou, Denis Mongin, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 15, 2025
Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs: Data From an International Collaboration of RegistriesRomain Aymon, Denis Mongin, Romain Guemara, et al.
Pageof 7